Transplantation of the relapsed AML into NSG mice caused CD19+ B-ALL that was genetically related to the relapsed AML, suggesting that the anti-CD19 treatment selected for clones that downregulated CD19 and acquired phenotypic changes toward the myeloid lineage (52). The gene discussed is CD19; the disease is acute myeloid leukemia.